ORAGENICS, INC. Proceeds from Convertible Debt
ORAGENICS, INC. (OGEN) reported Proceeds from Convertible Debt of $2.50 million for the 12-month period ending 2012-12-31, per its 10-K filed 2014-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2014-02-28
- ORAGENICS, INC. proceeds from convertible debt for the quarter ending 2012-12-31 was $1.75M.
- ORAGENICS, INC. proceeds from convertible debt for the quarter ending 2012-09-30 was $0.00.
- ORAGENICS, INC. proceeds from convertible debt for the quarter ending 2012-06-30 was $0.00.
- ORAGENICS, INC. proceeds from convertible debt for the quarter ending 2012-03-31 was $750.00K.
- ORAGENICS, INC. proceeds from convertible debt for fiscal 2012 was $2.50M, a 54.55% decline from fiscal 2011.
- ORAGENICS, INC. proceeds from convertible debt for fiscal 2011 was $5.50M, a 175.00% increase from fiscal 2010.
- ORAGENICS, INC. proceeds from convertible debt for fiscal 2010 was $2.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2012-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $1.75M derived: sum of 2 quarters · filed 2014-02-28 | $1.75M derived: sum of 3 quarters · filed 2014-02-28 | $2.50M 10-K · filed 2014-02-28 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-25 | $0.00 derived: sum of 2 quarters · filed 2013-10-25 | $750.00K 10-Q · filed 2013-10-25 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | $750.00K 10-Q · filed 2013-08-12 | ||
| 2012-03-31 | $750.00K 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | $5.50M 10-K · filed 2013-03-26 | |||
| 2010-12-31 | $2.00M 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |